Research Progress in Population Pharmacokinetics of Biologics for Inflammatory Bowel Disease

Inflammatory bowel disease(IBD) is a chronic, non-specific inflammatory disorder of the intestines. In recent years, biologics have emerged as a significant treatment approach for IBD, markedly improving patients’ clinical outcomes. However, their clinical application also presents multiple challenges, as notable individual variability exists in their pharmacokinetics and pharmacodynamics. With the growing number of population pharmacokinetic(PPK) studies on biologics for IBD, researchers are progressively uncovering the PPK characteristics of biologics and various factors influencing their clearance, providing strong support for the rational clinical use of these drugs. By searching three major authoritative databases: PubMed, EMBASE, and Web of Science, this article comprehensively summarizes and conducts an in-depth analysis of PPK model studies for biologics in IBD. It focuses on key factors and PPK models that affect biologic clearance, further discusses challenges in current research and future directions, and offers insights for the individualized application and further investigation of biologics in IBD patients.